These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12679259)

  • 1. Heated amphotericin to treat leishmaniasis.
    Bau P; Bolard J; Dupouy-Camet J
    Lancet Infect Dis; 2003 Apr; 3(4):188. PubMed ID: 12679259
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis.
    Barratt G; Legrand P
    Curr Opin Infect Dis; 2005 Dec; 18(6):527-30. PubMed ID: 16258327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
    Ortega V; Giorgio S; de Paula E
    J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of leishmaniasis.
    Balaña-Fouce R; Reguera RM; Cubría JC; Ordóñez D
    Gen Pharmacol; 1998 Apr; 30(4):435-43. PubMed ID: 9580315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrences of visceral leishmaniasis caused by Leishmania siamensis after treatment with amphotericin B in a seronegative child.
    Osatakul S; Mungthin M; Siripattanapipong S; Hitakarun A; Kositnitikul R; Naaglor T; Leelayoova S
    Am J Trop Med Hyg; 2014 Jan; 90(1):40-2. PubMed ID: 24277788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmaniasis: some recent developments in chemotherapy.
    Cook GC
    J Antimicrob Chemother; 1993 Mar; 31(3):327-30. PubMed ID: 8486567
    [No Abstract]   [Full Text] [Related]  

  • 7. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of visceral leishmaniasis.
    Ozsoylu S
    Turk J Pediatr; 2003; 45(3):280. PubMed ID: 14696814
    [No Abstract]   [Full Text] [Related]  

  • 10. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 11. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN; Pefanis A; Stathakis C; Helioti H; Kostakis A; Giamarellou H
    Clin Infect Dis; 1999 Jun; 28(6):1308-9. PubMed ID: 10451172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse cutaneous leishmaniasis in Ethiopia. II. Treatment.
    Bryceson AD
    Trans R Soc Trop Med Hyg; 1970; 64(3):369-79. PubMed ID: 5453496
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of visceral Leismaniasis in HIV patients with a new regimen of liposomal amphotericin].
    Canora Lebrato J; Troncoso García E; Escobar T; Hernández Quero J
    Med Clin (Barc); 2001 Mar; 116(10):395. PubMed ID: 11333677
    [No Abstract]   [Full Text] [Related]  

  • 14. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical localization of Leishmaniasis in an intestinal polyp.
    Zaffiri L; d'Ettorre G; Massetti AP; Mascellino MT; Mastroianni CM; Vullo V
    Infection; 2008 Mar; 36(2):187-8. PubMed ID: 18327682
    [No Abstract]   [Full Text] [Related]  

  • 16. [Subacute Mediterranean visceral leishmaniosis treated with a single injection of amphotericin B].
    Vandenbos F; Marty P; Rosenthal E; Delaunay P; Dellamonica P; Le Fichoux Y
    Presse Med; 2004 Sep; 33(15):1009-10. PubMed ID: 15523248
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B.
    Machado PR; Rosa ME; Guimarães LH; Prates FV; Queiroz A; Schriefer A; Carvalho EM
    Clin Infect Dis; 2015 Sep; 61(6):945-9. PubMed ID: 26048961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal drug delivery systems for the treatment of leishmaniasis.
    Tuon FF; Dantas LR; de Souza RM; Ribeiro VST; Amato VS
    Parasitol Res; 2022 Nov; 121(11):3073-3082. PubMed ID: 36112211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-leishmanial activity of a new formulation of amphotericin B.
    Dea-Ayuela MA; Rama-Iñiguez S; Sánchez-Brunete JA; Torrado JJ; Alunda JM; Bolás-Fernández F
    Trop Med Int Health; 2004 Sep; 9(9):981-90. PubMed ID: 15361111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.